Insulet (PODD) Expected to Post Quarterly Earnings on Wednesday

Insulet (NASDAQ:PODD) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $1.59 per share and revenue of $832.71 million for the quarter. Insulet has set its FY 2026 guidance at 6.460- EPS. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. During the same quarter in the prior year, the firm posted $1.17 earnings per share. The firm’s quarterly revenue was up 23.5% on a year-over-year basis. On average, analysts expect Insulet to post $6.51 EPS for the current fiscal year and $7.71 EPS for the next fiscal year.

Insulet Price Performance

Shares of PODD stock opened at $149.83 on Wednesday. The company’s fifty day simple moving average is $140.82 and its two-hundred day simple moving average is $181.92. Insulet has a 1 year low of $126.40 and a 1 year high of $354.88. The stock has a market capitalization of $10.39 billion, a price-to-earnings ratio of 28.01 and a beta of 1.11.

Analyst Ratings Changes

A number of equities analysts have recently commented on PODD shares. Evercore set a $180.00 price target on Insulet in a report on Monday, July 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Insulet in a research note on Monday, September 21st. Stifel Nicolaus dropped their price objective on Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Barclays raised Insulet to a “hold” rating in a report on Wednesday, October 7th. Finally, BTIG Research downgraded Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $186.68.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.